Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459222 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 229
- Enrollment target
NCT03459222 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 229 participants.
The verdict
NCT03459222, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 229 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Relatlimab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2025-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459222
The ClinicalTrials.gov registry entry for NCT03459222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT03459222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459222 about?
NCT03459222 is a clinical study titled "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread". The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
What is the current status of trial NCT03459222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 229 participants. The study started on 2018-05-30. Estimated completion is 2025-02-19.
What interventions are being tested in trial NCT03459222?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Relatlimab (BIOLOGICAL), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT03459222?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.